167 related articles for article (PubMed ID: 30656384)
41. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
42. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
[TBL] [Abstract][Full Text] [Related]
43. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
44. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
45. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
47. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.
Duke CM; Maguire CA; Keefer MC; Federoff HJ; Bowers WJ; Dewhurst S
Vaccine; 2007 Oct; 25(42):7410-21. PubMed ID: 17868958
[TBL] [Abstract][Full Text] [Related]
48. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
[TBL] [Abstract][Full Text] [Related]
49. Immunodominance of Adenovirus-Derived CD8
Schöne D; Hrycak CP; Windmann S; Lapuente D; Dittmer U; Tenbusch M; Bayer W
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768877
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.
Iankov ID; Haralambieva IH; Galanis E
Vaccine; 2011 Feb; 29(8):1710-20. PubMed ID: 21182995
[TBL] [Abstract][Full Text] [Related]
51. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
[TBL] [Abstract][Full Text] [Related]
52. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
53. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
Front Immunol; 2019; 10():2941. PubMed ID: 31921191
[TBL] [Abstract][Full Text] [Related]
54. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
[TBL] [Abstract][Full Text] [Related]
55. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
[TBL] [Abstract][Full Text] [Related]
56. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
57. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
Hutzler S; Erbar S; Jabulowsky RA; Hanauer JRH; Schnotz JH; Beissert T; Bodmer BS; Eberle R; Boller K; Klamp T; Sahin U; Mühlebach MD
Sci Rep; 2017 Dec; 7(1):16892. PubMed ID: 29203786
[TBL] [Abstract][Full Text] [Related]
58. Attenuated measles virus as a vaccine vector.
Zuniga A; Wang Z; Liniger M; Hangartner L; Caballero M; Pavlovic J; Wild P; Viret JF; Glueck R; Billeter MA; Naim HY
Vaccine; 2007 Apr; 25(16):2974-83. PubMed ID: 17303293
[TBL] [Abstract][Full Text] [Related]
59. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
60. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
